biostudies-literatureUnknown160(9)Drucker AM<h4>Importance</h4>There are multiple approved systemic treatments for atopic dermatitis. Lebrikizumab is a newly licensed biologic medication that has been compared to placebo in clinical trials but not to other systemic treatments.<h4>Objective</h4>To compare reported measures of efficacy and safety of lebrikizumab to other systemic treatments for atopic dermatitis in a living systematic review and network meta-analysis.<h4>Data sources</h4>The Cochrane Central Register of Controlled Trials, MEDLINE, Embase, the Latin American and Caribbean Health Science Information database, the Global Resource of Eczema Trials database, and trial registries were searched from inception through November 3, 2023.<h4>Study selection</h4>Randomized clinical trials evaluating 8 or more weeks of treatment wJAMA dermatology936-944https://www.ebi.ac.uk/biostudies/studies/S-EPMC11255974biostudies-literatureSystemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update.PMC11255974Rochwerg BArents BWMYiu ZZNBurton TEllis AGSpuls PISchmitt JPrieto-Merino DMohan TMalek RDrucker AMLam MDi Giorgio SFlohr CfalseSystemic Immunomodulatory Treatments for Atopic Dermatitis: Living Systematic Review and Network Meta-Analysis Update.<h4>Importance</h4>There are multiple approved systemic treatments for atopic dermatitis. Lebrikizumab is a newly licensed biologic medication that has been compared to placebo in clinical trials but not to other systemic treatments.<h4>Objective</h4>To compare reported measures of efficacy and safety of lebrikizumab to other systemic treatments for atopic dermatitis in a living systematic review and network meta-analysis.<h4>Data sources</h4>The Cochrane Central Register of Controlled Trials, MEDLINE, Embase, the Latin American and Caribbean Health Science Information database, the Global Resource of Eczema Trials database, and trial registries were searched from inception through November 3, 2023.<h4>Study selection</h4>Randomized clinical trials evaluating 8 or more weeks of treatment w2024-01-01T00:00:00Z2024 Sep2025-04-20T00:46:45.79Z2025-04-20T00:46:45.79ZS-EPMC112559743901805810.1001/jamadermatol.2024.2192